FDA-CVM works to address concerns about pergolide supplies.
D000818:Animals; D017277:Drug Approval; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses; D018696:Neuroprotective Agents / Q000009:adverse effects* / Q000627:therapeutic use; D010479:Pergolide / Q000009:adverse effects* / Q000627:therapeutic use; D010900:Pituitary Diseases / Q000188:drug therapy / Q000662:veterinary*; D052716:Pituitary Gland, Intermediate; D014481:United States
D018696:Neuroprotective Agents; D010479:Pergolide